Tetracaine

Tetracaine
Clinical data
Trade namesPontocaine, Ametop, Dicaine, others
AHFS/Drugs.comMonograph
MedlinePlusa682640
License data
Pregnancy
category
  • AU: B2
Routes of
administration
Topical
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) / S2
  • BR: Class C1 (Other controlled substances)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding75.6
Identifiers
  • 2-(Dimethylamino)ethyl 4-(butylamino)benzoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.002.106
Chemical and physical data
FormulaC15H24N2O2
Molar mass264.369 g·mol−1
3D model (JSmol)
  • O=C(OCCN(C)C)c1ccc(NCCCC)cc1
  • InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3 Y
  • Key:GKCBAIGFKIBETG-UHFFFAOYSA-N Y
  (verify)

Tetracaine, also known as amethocaine, is an ester local anesthetic used to numb the eyes, nose, or throat. It may also be applied to the skin before starting intravenous therapy to decrease pain from the procedure. Typically it is applied as a liquid to the area. Onset of effects when used in the eyes is within 30 seconds and last for less than 15 minutes.

Common side effects include a brief period of burning at the site of use. Allergic reactions may uncommonly occur. Long-term use is generally not recommended as it may slow healing of the eye. It is unclear if use during pregnancy is safe for the baby. Tetracaine is in the ester-type local anesthetic family of medications. It works by blocking the sending of nerve impulses.

Tetracaine was patented in 1930 and came into medical use in 1941. It is on the World Health Organization's List of Essential Medicines